Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

STATUS

Recruiting
participants needed

12
sponsor

Genzyme, a Sanofi Company

Send

Updated on 19 February 2024

See if I qualify

hemophilia

antihemophilic factor

factor ix

bethesda assay

fitusiran

haemophilia a

Summary

Primary Objective:

To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

Secondary Objective:

To characterize the safety and tolerability
To characterize the pharmacokinetics (PK)

Description

Study duration per participant is approximately 160 weeks, including a 12-week fitusiran efficacy period

Details

Condition	Hemophilia A, hemophilia, hemophilia
Age	1years - 11years
Treatment	Fitusiran
Clinical Study Identifier	NCT03974113
Sponsor	Genzyme, a Sanofi Company
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male, aged 1 to <12 years at the time of enrollment
	Severe hemophilia A or B (Factor VIII (FVIII) <1% or Factor IX (FIX) 2%)
	Participants must have inhibitory antibodies to FVIII or FIX and must meet one of the following Nijmegen-modified Bethesda assay results criteria
	Inhibitor titer of 0.6 BU/mL at screening, OR
	Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of 2 consecutive titers 0.6 BU/mL, OR
	Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of anamnestic response
	Adequate peripheral venous access, as determined by the Investigator, to allow the blood draws required by the study protocol
	Weight requirements at the time of enrollment: 8 to <45 kg
	Willing and able to comply with the study requirements and to provide signed written informed consent obtained from parent(s)/legal guardian (hereinafter the "parent") and written or oral assent obtained from participant, per local and national requirements
Exclusion Criteria
	Known co-existing bleeding disorders other than hemophilia A or B
	Antithrombin (AT) activity <60% at Screening
	Co-existing thrombophilic disorder
	Clinically significant liver disease
	Active Hepatitis C virus infection
	Acute or chronic Hepatitis B virus infection
	Acute Hepatitis A or hepatitis E infection
	HIV positive with a CD4 count of <400 cells/L
	History of arterial or venous thromboembolism, unrelated to an indwelling venous access
	Inadequate renal function
	History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc)
	Subjects with central or peripheral indwelling catheters, with history of venous access complications leading to hospitalization and/or systemic anticoagulation therapy
	History of intolerance to subcutaneous (SC) injection(s)
	Any other conditions or comorbidities that would make the patient unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

hemophilia

antihemophilic factor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B